With a new direct-to-consumer platform, transparent pricing, and backing from tech and marketing partners ARTI and Myosin, ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, Department of Chemistry, Texas A&M University, College Station, Texas 77845, and Laboratoire de Chimie ...

Critical illness myopathy (CIM) detrimentally affects muscle function in ICU patients, with a dramatic loss of muscle mass and function where the loss in specific force exceeds the loss in muscle mass ...

Yilan Hua is a leader in the pack of a new generation of Chinese supermodels, with ambitions that could take her beyond the runways. By Elizabeth Paton Reporting from Paris There is one model who ...

Abstract: The conformational changes of the myosin head due to the ATP hydrolysis determine the tilting of the head and the consequent sliding of the actin filament. A mathematical model of the myosin ...

Department of Applied Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan Department of Complex Systems Science, Nagoya University, Nagoya 464-8601, Japan Fukui Institute for ...

Myosin II is a molecular motor that generates force and motion in muscle cells. During muscle contraction, many myosin II motors bind to the same actin filament, like people pulling on a rope in a tug ...

Force measurements on cardiac myosin molecules and polymerized myofilaments demonstrated that single molecules transition back and forth between three molecular conformations when bound to an actin ...

Since the discovery of muscle in the 19th century, myosins as molecular motors have been extensively studied. However, in the last decade, a new functional super-relaxed (SRX) state of myosin has been ...

This is the first study to show that the impact of myosin modulator mavacamten (Myk461) to reduce myocardial force generation is modulated by the expression level of cardiac myosin binding protein‐C.